Dr. Stanton McHardy

Description:

Stanton F. McHardy, Ph.D., is an Associate Professor and Director of the Center for Innovative Drug Discover (CIDD) at the University of Texas at San Antonio (UTSA). McHardy is a former Associate Director of Neuroscience at Pfizer (1996-2006) where he successfully led teams in the discovery of clinical drug candidates for addiction, schizophrenia and ADHD. With over 28 years of expertise in pharmaceutical R&D, his work spans neuroscience, cancer and non-opioid pain drug discovery, leading to multiple investigational new drug applications.

Working days:

Tuesday, Wednesday, Saturday

Explore My Expertise :

He currently directs a collaborative research center and research programs focused on various drug discovery approaches to neuroscience diseases, infectious diseases, non-opioid pain and cancer. His current research focuses on the design, synthesis and structure-activity relationships of small molecules with therapeutically relevant biological activity, specifically in natural products, brain-penetrant sub-type specific kinase inhibitors, pro-drugs for sulfotransferases and novel PROTAC (proteolysis targeting chimera) ligands. He holds the Max and Minnie Tomerlin Voelcker Endowment for the Center of Innovative Drug Discovery (CIDD), the UTSA Innovator of the year award (2019) and was inducted as a Fellow in the National Academy of Inventors in 2024. He holds a total of 42 patents (20 US issued, 22 foreign) in the field of Medicinal Chemistry and Drug Discovery and has published 86 peer-reviewed journal articles.

“His collaborative work with Dr. Cara Gonzales resulted in innovative treatments for oral cancer, including the development of CIDD99.”